Research programme: macromolecular drug conjugates - Prolynx

Drug Profile

Research programme: macromolecular drug conjugates - Prolynx

Alternative Names: Hydrogel-exenatide - Prolynx; Hydrogel-octreotide - Prolynx; PEG-exenatide - Prolynx; PEG-octreotide - Prolynx

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Prolynx
  • Class Camptothecins; Drug conjugates; Polyethylene glycols
  • Mechanism of Action DNA topoisomerase I inhibitors; Glucagon like peptide 1 receptor agonists; Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acromegaly; Cancer; Type 2 diabetes mellitus

Highest Development Phases

  • Preclinical Cancer; Ear disorders
  • No development reported Acromegaly; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acromegaly in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (SC, Implant)
  • 16 Jul 2016 No recent reports of development identified for research development in Acromegaly in USA (SC, Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top